This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Tsao MN, Rades D, Wirth A, Lo SS, Danielson BL, Gaspar LE, et al. Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol 2012; 2: 210-25. 10.1016/j.clon.2012.03.008TsaoMNRadesDWirthALoSSDanielsonBLGasparLEet alRadiotherapeutic and surgical management for newly diagnosed brain metastasis(es): an American Society for Radiation Oncology evidence-based guidelinePract Radiat Oncol20122210–2510.1016/j.clon.2012.03.008Open DOISearch in Google Scholar
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019; 69: 7-34. 10.3322/caac.21551SiegelRLMillerKDJemalA.Cancer statistics, 2019CA Cancer J Clin2019697–3410.3322/caac.21551Open DOISearch in Google Scholar
Rades D, Kieckebusch S, Lohynska R, Veninga T, Stalpers LJ, Dunst J, et al. Reduction of overall treatment time in patients irradiated for more than three brain metastases. Int J Radiat Oncol Biol Phys 2007; 69: 1509-13.RadesDKieckebuschSLohynskaRVeningaTStalpersLJDunstJet alReduction of overall treatment time in patients irradiated for more than three brain metastasesInt J Radiat Oncol Biol Phys2007691509–1310.1016/j.ijrobp.2007.05.014Search in Google Scholar
Mulvenna P, Nankivell M, Barton R, Faivre-Finn C, Wilson P, McColl E, et al. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. Lancet 2016; 388: 2004-14. 10.1016/S0140-6736(16)30825-XMulvennaPNankivellMBartonRFaivre-FinnCWilsonPMcCollEet alDexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trialLancet20163882004–1410.1016/S0140-6736(16)30825-XOpen DOISearch in Google Scholar
Rades D, Panzner A, Dziggel L, Haatanen T, Lohynska R, Schild SE. Dose-escalation of whole-brain radiotherapy for brain metastasis in patients with a favorable survival prognosis. Cancer 2012; 118: 3853-9. 10.1002/cncr.26680RadesDPanznerADziggelLHaatanenTLohynskaRSchildSEDose-escalation of whole-brain radiotherapy for brain metastasis in patients with a favorable survival prognosisCancer20121183853–910.1002/cncr.26680Open DOISearch in Google Scholar
DeAngelis LM, Delattre JY, Posner JB. Radiation-induced dementia in patients cured of brain metastases. Neurology 1989; 39: 789-96.DeAngelisLMDelattreJYPosnerJBRadiation-induced dementia in patients cured of brain metastasesNeurology198939789–9610.1212/WNL.39.6.789Search in Google Scholar
Gondi V, Pugh SL, Tome WA, Caine C, Corn B, Kanner A, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J Clin Oncol 2014; 32: 3810-6. 10.1200/JCO.2014.57.2909GondiVPughSLTomeWACaineCCornBKannerAet alPreservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trialJ Clin Oncol2014323810–610.1200/JCO.2014.57.2909Open DOISearch in Google Scholar
Brown PD, Pugh S, Laack N, Wefel JS, Khuntia D, Meyers C, et al.; Radiation Therapy Oncology Group (RTOG): Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol 2013; 15: 1429-37. 10.1093/neuonc/not114BrownPDPughSLaackNWefelJSKhuntiaDMeyersCet alRadiation Therapy Oncology Group (RTOG): Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trialNeuro Oncol2013151429–3710.1093/neuonc/not114Open DOISearch in Google Scholar
Sperduto PW, Chao ST, Sneed PK, Luo X, Suh J, Roberge D, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys 2010; 77: 655-61. 10.1016/j.ijrobp.2009.08.025SperdutoPWChaoSTSneedPKLuoXSuhJRobergeDet alDiagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patientsInt J Radiat Oncol Biol Phys201077655–6110.1016/j.ijrobp.2009.08.025Open DOISearch in Google Scholar
Rades D, Dziggel L, Segedin B, Oblak I, Nagy V, Marita A, et al. A simple survival score for patients with brain metastases from breast cancer. Strahlenther Onkol 2013; 189: 664-7. 10.1007/s00066-013-0367-5RadesDDziggelLSegedinBOblakINagyVMaritaAet alA simple survival score for patients with brain metastases from breast cancerStrahlenther Onkol2013189664–710.1007/s00066-013-0367-5Open DOISearch in Google Scholar
Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.KaplanELMeierPNon parametric estimation from incomplete observationsJ Am Stat Assoc195853457–8110.1080/01621459.1958.10501452Search in Google Scholar
Rades D, Dziggel L, Nagy V, Segedin B, Lohynska R, Veninga T, et al. A new survival score for patients with brain metastases who received whole-brain radiotherapy (WBRT) alone. Radiother Oncol 2013; 108: 123-7. 10.1016/j.radonc.2013.06.009RadesDDziggelLNagyVSegedinBLohynskaRVeningaTet alA new survival score for patients with brain metastases who received whole-brain radiotherapy (WBRT) aloneRadiother Oncol2013108123–710.1016/j.radonc.2013.06.009Open DOISearch in Google Scholar
Mehta MP, Rodrigus P, Terhaard CH, Rao A, Suh J, Roa W, et al. Survival and neurologic outcomes in a randomizedtrial of motexafin gadolinium and whole-brain radia-tion therapy in brain metastases. J Clin Oncol 2003; 21: 2529-36. 10.1200/JCO.2003.12.122MehtaMPRodrigusPTerhaardCHRaoASuhJRoaWet alSurvival and neurologic outcomes in a randomizedtrial of motexafin gadolinium and whole-brain radia-tion therapy in brain metastasesJ Clin Oncol2003212529–3610.1200/JCO.2003.12.122Open DOISearch in Google Scholar
Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997; 37: 745-51.GasparLScottCRotmanMAsbellSPhillipsTWassermanTet alRecursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trialsInt J Radiat Oncol Biol Phys199737745–5110.1016/S0360-3016(96)00619-0Search in Google Scholar
Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database Int J Radiat Oncol Biol Phys 2008; 70: 510-4. 10.1016/j.ijrobp.2007.06.074SperdutoPWBerkeyBGasparLEMehtaMCurranWA new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG databaseInt J Radiat Oncol Biol Phys200870510–410.1016/j.ijrobp.2007.06.074Open DOISearch in Google Scholar
